2016-08-29

[#DIV28SUPER] Deadline for Symposium Submission for 2017 Collaborative Perspectives on Addiction Meeting: September 30th!

Dear Colleagues,

 

Please note that the September 30th deadline to submit a symposium proposal for next year’s Fifth Annual Collaborative Perspectives on Addiction (CPA) Meeting is fast approaching.

 

CPA will take place on March 24th and 25th, 2017 in Albuquerque, NM. Our theme this year will be Addiction at the Crossroads of Mental and Physical Health. Symposium proposals that fit the theme closely are preferred, however, we are happy to consider high quality symposium proposals on all topics of likely interest to conference attendees.

 

CPA is a small but growing meeting that offers fantastic opportunities for networking for investigators, but particularly for students and trainees, in addition to learning about the latest science in addiction psychology.

 

You can find the call for proposals here: http://www.apa.org/divisions/div50/doc/2017-cpa-call.pdf

 

For more information contact Drs. Robert Leeman (robert.leeman@ufl.edu) or James Murphy (jgmurphy@memphis.edu).

 


[#DIV28SUPER] NIDA Neuroscience Update September 29, 2016: Funding Opportunities

Table of Contents

 

I.                    PAR-15-120: Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01)

II.                  PAR-16-357: The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1)

III.                PAR-16-291: Integrative Research on Polysubstance Abuse and Addiction (R21/R33)

IV.                PAR-16-383: Chemistry Science Track Award for Rapid Transition (C/START)(R03)

V.                  PAR-16-384: Chemical Discovery (CHEM) Award (R21/R33)

VI.                RFA-DA-17-013: The Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)   

------------------

 

I.                  PAR-15-120: Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01) - See more at: http://grants.nih.gov/grants/guide/pa-files/PAR-15-120.html#sthash.BmUCzrQH.dpuf

Next Application Deadline: October 20, 2016

The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred  non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping.

-----------------

II.               PAR-16-357: The Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1).  http://grants.nih.gov/grants/guide/pa-files/PAR-16-357.html.

Letter of Intent: September 19, 2016

Application Deadline: October 19, 2016 by 5:00PM local time of application organization.

This funding opportunity is for early stage investigators who are within 10 years of completing their terminal degree, hold an independent career position by September 1, 2016, and has not received a significant independent research award such as an R01.  I encourage early stage investigators outside of the field of drug abuse and addiction to apply.

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.  These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction.  Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply.  The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.  

If you are interested please read the entire announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-16-357.html.

----------------------

III.            PAR-16-291: Integrative Research on Polysubstance Abuse and Addiction (R21/R33) http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html

 

Next Application Deadline:  October 16, 2016

 

NIDA has recently published a new FOA entitled Integrative Research on Polysubstance Abuse and Addiction (http://grants.nih.gov/grants/guide/pa-files/PAR-16-291.html). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange. If you have further inquiries regarding this new announcement, please contact Dr. Shelley Su at shelley.su@nih.gov.

-----------------------

IV.            PAR-16-383: Chemistry Science Track Award for Rapid Transition (C/START)(R03)  http://grants.nih.gov/grants/guide/pa-files/PAR-16-383.html

Next Application Deadline: October 16, 2016

The National Institute on Drug Abuse (NIDA) seeks to facilitate the entry of new/early stage investigators (ESIs) into substance use disorder (SUD) research. ESIs are invited to submit applications for small scale, innovative chemical/pharmacological pilot research projects. Importantly, the C/START award is intended to enable an ESI the opportunity to gather preliminary data in support of subsequent research grants (e.g., R21/R33 [CHEM], R21 or R01) or drug development funding opportunities that, in the long term, help to launch the ESI’s scientific career. 

------------------------

V.               PAR-16-384: Chemical Discovery (CHEM) Award (R21/R33) http://grants.nih.gov/grants/guide/pa-files/PAR-16-384.html

Next Application Deadline: October 16, 2016

The purpose of this FOA is to support the development of chemical probes that aid basic research investigations on substance use disorders (SUDs) or identify new lead chemical scaffolds with potential for structure activity relationship (SAR) studies on SUDs. In the long term, it is hoped that these lead chemical scaffolds will provide a greater number of pharmacological tools for basic research and possible drug candidates for medications development.

------------------------------

VI.        RFA-DA-17-013: The Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01) http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-17-013.html

Application Due Date: November 18, 2016

The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms of HIV infection-induced immune activation and inflammation in the presence of antiretroviral therapy (ART) agents and drugs of abuse. The ultimate goal is to obtain information for developing therapeutic interventions for attenuating chronic inflammation-associated comorbidities as well as for restoring or improving ART efficacy in HIV-infected drug-abusing populations. 

 

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

2016-08-28

[#DIV28SUPER] Post-Doctoral Fellowship in Neuropsychopharmacology

Post-Doctoral Fellowship in Neuropsychopharmacology

 

A post-doctoral position with competitive salary and benefits is available in the Department of Neurosciences at the Medical University of South Carolina (MUSC) with a focus on the neurobiology of addiction, relapse to drugs of abuse, and sex differences in addiction.  The laboratory uses a variety of behavioral, pharmacological, and neurochemical approaches to answer key questions in addiction.  Expertise in behavioral testing and rodent surgery is desirable, but not necessary.  Fellows will have opportunities to participate in several NIDA center projects.  This position is currently open.

 

MUSC is located in the beautiful coastal city of Charleston, a historic seaport famous for its architecture, gardens, and restaurants.  The presence of nearby colleges, beaches and rivers, and a pleasant subtropical climate add to Charleston's many charms.

 

To apply, send a letter of interest, CV, and names of 3 references by e-mail to:

 

Dr. Carmela M Reichel                            E-mail: reichel@musc.edu

Department of Neurosciences

173 Ashley Avenue, BSB416B

Medical University of South Carolina

Charleston, SC 29425


2016-08-26

[DIV28_ANNOUNCEMENT] ASU psychology dept chair ad

The Psychology department at Arizona State University is recruiting a new department chair. See the attached for more information.

 

2016-08-23

[#DIV28SUPER] The Division of Basic Neuroscience at the National Institute on Drug Abuse at NIH seeks to hire two Health Scientist Administrators. Application deadline August 29, 2016. Salary Range $92,145.00 to $141,555.00 / Per Year

The NIDA/Division of Basic Neuroscience (DNB) (https://www.drugabuse.gov/about-nida/organization/divisions/division-neuroscience-behavior-dnb-0 is hiring two Health Scientist Administrators in the following areas:

Position 1

The selectee to this position must possess expertise in computational neuroscience and have the knowledge and training necessary to develop a portfolio in big data science.  The incumbent will serve as the NIDA/DNB representative to Trans-NIH initiatives such as the Big Data to Knowledge initiative and its various sub workgroups, The BRAIN® initiative, the inter-Agency Modeling and Analysis workgroup and many others.

 

 

Position 2

 

The selectee must have the knowledge and training in order to provide expert advice in program planning, solicitation, and evaluation, and to manage administrative functions related to research grants, contracts, and interagency agreements supporting research projects and to foster and manage our portfolio and work flow.

 

Current Federal employees should follow this link to apply:

 

https://www.usajobs.gov/GetJob/ViewDetails/448385400/

 

Individuals who do not possess government status, but who are US citizens, please follow this link to apply: https://www.us   ajobs.gov/GetJob/ViewDetails/448407700/

 

Open date: Monday 8/22/2016

Close date: Monday 8/29/2016

Location: Rockville, MD

Salary Range: $92,145.00 to $141,555.00 / Per Year

Series and Grade:  GS-0601-13/14

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

2016-08-16

[DIV28_ANNOUNCEMENT] Call for Papers: Special section of PAB

Call for Papers
Psychology of Addictive Behaviors

APA's 125th Anniversary Special Section on
Effective Treatments for Addictive Disorders: Past, Present and Future

The year 2017 marks the 125th anniversary of APA and the 30th anniversary of Psychology of Addictive Behaviors. To commemorate this occasion, the journal is planning a special section on effective treatments for substance use and other addictive disorders. Over this past century, the medical profession began recognizing substance use disorders as medical conditions, and treatments have changed markedly, especially in the past few decades with the advent of medications as well as efficacious psychosocial treatments.

For this special section, Psychology of Addictive Behaviors is seeking review articles and meta-analyses of specific interventions. Examples of topics include (but are not limited to) comprehensive review articles focused on the background and efficacy of: (1) motivational enhancement therapy; (2) brief interventions (3) cognitive-behavioral therapy; (4) contingency management interventions; (5) pharmacotherapies (methadone, buprenorphine, naloxone, or smoking cessation medications); (6) 12-step interventions; (7) mindfulness-based therapies; or (8) family therapies. We also welcome meta-analyses of interventions.

In addition to reviews or meta-analyses of specific interventions, we are encouraging articles examining the efficacy of different interventions within specific populations. Review papers or meta-analyses may, for example, compare different psychosocial approaches for treating alcohol use disorder, opioid use disorders, stimulant use disorders, marijuana use disorder, smoking, or gambling disorder. They may also address interventions for substance use disorders in adolescents or older adults, or for common comorbid conditions such as post-traumatic stress disorder and substance use disorders or schizophrenia and smoking.

Successful papers will provide comprehensive and balanced summaries of the intervention(s), along with evidence of efficacy both in the short and long term. They will outline the strengths and limitations of the approach(es) and available data, as well as identify areas in which data are lacking or mixed. Papers should also highlight future directions related to the specific intervention(s).

The special section articles will serve as authoritative reviews of interventions through 2016. They should also guide future efforts to improve treatments and outcomes for addictive behaviors.

Please submit manuscripts through the APA Portal (http://www.apa.org/pubs/journals/adb/). The cover letter should indicate that the authors wish the paper to be considered for publication in the Special Section on Effective Treatments. Submissions will be peer-reviewed and must adhere to basic journal requirements. The one exception is that papers may exceed the usual 40 page limit to accommodate reference sections. For this Special Section, the main text (introduction through discussion) should not exceed 30 pages of double spaced text, but there is no limitation on references. The deadline for consideration for the special section is January 15, 2017.

Psychology of Addictive Behaviors aims to achieve a rapid turnaround on all submissions. The average time to initial decision is under one month. Although we only accept less than 25% of submissions, over 90% of papers that are invited for a revision are ultimately accepted.

Please direct questions or inquires to the editor-in-chief, Nancy Petry (npetry@uchc.edu), Associate Editors (Tammy Chung, Craig Colder, Sarah Feldstein Ewing, Jim McKay, Sherry McKee, Tom Piasecki, Damaris Rohsenow, John Roll, or Katie Witkiewitz) or Guest Editors: Kathleen Carroll (Kathleen.Carroll@yale.edu), Carlo DiClemente (diclemen@umbc.edu), or Ken Winters (winte001@umn.edu).

_____________________div28announce____________________________
A Division 28 announcement-only list subscribers corner: http://lists.apa.org

[#DIV28SUPER] Fwd: [DIVOFFICERS] APA Science Directorate student awards

The APA Science Directorate is offering awards to graduate student researchers in 2016. Please see the link below to learn more about both the APA Dissertation Research Award and the Early Graduate Student Researcher Award. The application deadline for both programs is September 16, 2016, and awards range from $1000 to $5000.

  

http://www.apa.org/science/about/psa/2016/07/dissertation-research.aspx

 

 

 

Kirk Waldroff | Director, Communications

APA Science Directorate
American Psychological Association
750 First Street NE, Washington, DC 20002-4242
Tel: 202.336.6192 |  Fax: 202.336.5953

email: kwaldroff@apa.org | www.apa.org

   

 


 

 

 

 

 

 

 

 

 

 


_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Faculty Position in Health Disparities at Auburn University

Auburn University is launching an exciting new cluster-hire initiative that will support six new faculty positions in Psychology (this position), Human Development and Family Studies, Nutrition, Health Outcomes and Policy, Kinesiology and Nursing. The overarching goal of the initiative is to develop an interdisciplinary group of independent research programs and a central resource for those interested in health disparities across ten colleges and schools across campus.

The specific area is open but we welcome applications from people in all aspects of substance abuse and psychopharmacology, including human studies and experimental models. 

We anticipate a diverse range of research approaches across the initiative, including large-scale population-based studies, small- or large-scale interventions, or laboratory based approaches using experimental animal models. The key element is a record aimed at characterizing, understanding, or alleviating disparities in health outcomes associated with income, ethnicity, sex, sexual identify, age, disability, geographic location, or other inequities.  

Information about the department and the initiative can be found at http://www.cla.auburn.edu/psychology/health-disparities/

 Please forward to interested individuals or relevant lists.

 I would be happy to answer any questions about this position.

 

--------------------------------------------------------------------------
Chris Newland, Ph. D.

Professor, Department of Psychology                          

226 Thach Hall 

342 W. Thach Ave      
Auburn University

Alabama 36849-5212
Office: 334 844-6479      Lab:     334 844-3295      Fax:     334 844-4447
www.auburn.edu/~newlamc/PersonalWeb

---------------------------------------------------------------------------

 

[#DIV28SUPER] PCORI: Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain

Dear Colleagues,

PCORI didn’t receive enough meritorious proposals to spend the $40 million allocated for the PFA described below.  The PCORI Board of Governors voted today to reopen the PFA to spend out the remaining $19 million.  I’ll forward the formal announcement as soon as it becomes available. Please consider applying.

Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain | View the funding announcement | View the topic brief

·         Among patients with chronic non-cancer pain on moderate to high-dose long-term opioid therapy, what is the comparative effectiveness of strategies for reducing/eliminating opioid use while managing pain?

·         Among patients on moderate/low-dose long-term opioid therapy, what are the comparative effectiveness and harms of strategies used to limit dose escalation?

Best,

-geoff

 

 

Geoffrey K. Mumford, Ph.D. | Associate Executive Director for Government Relations

Science Directorate
American Psychological Association
750 First Street NE, Washington, DC 20002-4242
Tel: 202.336.6067 |  Fax: 202.336.6063

email: gmumford@apa.org | www.apa.org

   

 

P Most people consider the environment before printing their email.

 

 

 

 

 

2016-08-13

[#DIV28M] VTCRI Addiction Recovery Research Postdoc Opportunity

VTCRI Addiction Recovery Research Center Postdoc Opportunity

 

The Addiction Recovery Research Center of the Virginia Tech Carilion Research Institute has NIH-funded postdoctoral research associate opportunities in a state-of-the-art research facility. The postdoctoral associate will contribute to NIDA, NIAAA, NCI, and NIDDK funded research studies employing behavioral economics and neuro-economic approaches to address addiction, obesity, and other health behaviors using both human laboratory and clinical trial methodologiesThese positions will participate in studies using our International Quit & Recovery Registry and studies employing neuro-modulatory transcranial magnetic stimulation (TMS) and fMRI technologies. Research duties will involve authoring and co-authoring manuscripts, assisting with grant writing, and collaborating with investigators. The Addiction Recovery Research Center has an exceptional track record of helping postdoctoral associates further their careers as investigators. 

 

Appointment:  2-3 yrs.

 

Eligibility: Applicants should be interested in pursuing a career in addiction, obesity, and health behaviors research. Applicants should also be effective and productive writers and have research training in clinical, experimental, or cognitive psychology or related disciplines. Applicants must have completed a Ph.D. in psychology, behavior analysis, or a related field. Women and minorities are strongly encouraged to apply.

 

Benefits: Full-time annual salary, medical insurance coverage, and travel funds supported by NIH grants. Translational research training and career development opportunities are provided as part of this position.

 

For more information:  Contact Ms. Patsy Marshall (patsym@vtc.vt.edu).

 

To apply: Send cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to:  Dr. Warren K. Bickel c/o Ms. Patsy Marshall (patsym@vtc.vt.edu). Applications will be reviewed on an ongoing basis.

 

About us: The Addiction Recovery Research Center (ARRC) was established in 2011 as part of the Virginia Tech Carilion Research Institute, an innovative partnership of Virginia Tech and Carilion Clinic. The facilities and research teams are world-class and focus on transdisciplinary research on the scientific underpinnings of health and a range of diseases and disorders. Virginia Tech Carilion Research Institute represents a new model for biomedical and behavioral science in which creative scientists can approach major problems with breadth and depth in a nurturing and intellectually challenging environment. 

 

About Roanoke, Virginia: Roanoke, Virginia is located in Southwest Virginia in the foothills of the Appalachian Mountains and accessible by the Blue Ridge Parkway. Roanoke is a vibrant community with an active downtown full of restaurants, theaters, museums, and a new amphitheater that is home to many seasonal festivals and music events. Roanoke also offers great opportunities for an active outdoor lifestyle with 30 miles of greenway connecting charming neighborhoods and beautiful parks along the Roanoke River.

 


               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
phone: (859) 257-5383
facsimile: (859) 257-7684


Associate Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2016-08-11

[#DIV28SUPER] NYTimes: Obama Administration Set to Remove Barrier to Marijuana Research

http://www.nytimes.com/2016/08/11/science/obama-administration-set-to-remove-barrier-to-marijuana-research.html?smprod=nytcore-iphone&smid=nytcore-iphone-share

The new policy could spur broad scientific study of a drug being used to treat dozens of diseases despite little rigorous evidence of its effectiveness.


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

2016-08-06

[#DIV28SUPER] Div 28 Sunday Agenda

Cognition, Memory, and Behavior of Sibling Groups With FASD---Nature and Nurture
(12:00 – 1:50 PM, Convention Center Room 103)
D. Neal
Fetal Alcohol Spectrum Disorders: Definitions, History, and the Role of Environment
 S. Han
Intellectual Functioning for Sibling Groups With FASD: Gender, Age, and Time in a Stable Environment
J. Seiders
Memory Functioning in Sibling Groups With FASD: The Influence of Stability
C. Leonce
Early Intervention: Decreasing Behavioral Problems in Sibling Groups With FASD
G. Andrews (Discussant)

--

Mollie Miller, Ph.D.
Postdoctoral Research Associate
Brown University
Center for Alcohol and Addiction Studies
121 South Main St., Box G-S121-4
Providence, RI 02912
P:401-863-6631

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Live Stream of "fifty years of div28" NOW

The symposium is streaming live from Denver ..
Facebook Group APA Division of Psychopharmacology..
Join today!

Sent from my iPhone

_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] Great science on deck at APA today

​Below is today's APA Division 28 agenda-  come join us for these great sessions!



Cannabis and Cognition – Harvesting Scientific Discoveries Toward Improvements in Treatment
(8:00 – 9:50 AM, Convention Center Room 205)
F. Filbey
Potential Mechanisms of Cognitive Dysfunction in Cannabis Users
 J. Cousijn
Can We Use Neurocognitive Functions to Predict the Course of Cannabis Use and Dependence?
J. Gilman
Altered Social Cognition Among Young Adult Marijuana Users
 C. Stanger
Working Memory Training in Adolescent Cannabis Users
 I. Grant (Discussant)


Division 28 Poster Session: 9:00 – 9:50 AM
(Convention Center Exhibit Hall ABC)


Division 28 Presidential Address
(10:00 – 10:50 AM, Convention Center Room 104)
S. Sigmon
Developing and Evaluating Novel Treatments for Opioid Dependence 

 
Business Meeting
 (11:00 – 11:50 AM, Convention Center Room 104)
(Open to all Members of Division 28)


Fifty Years of Division 28 – Our Remarkable Past and Bright Future 
(12:00 – 1:50 PM (CE), Convention Center Room 301)
W. Bickel
In the Beginning a Response Was Reinforced: Conceptual Expansion in Addiction Science
 M. Carroll
Risk Factors for Drug Addiction and Novel Treatments: Preclinical Models
 R. Balster
The Role of Behavioral Pharmacology and Toxicology Research in Regulatory Science
M. Stitzer
Nicotine and Tobacco Research in Division 28
 S. Higgins
Division 28 and the Development of Contingency Management Interventions for Substance Use Disorders


Marijuana as Medicine: Can We See Past the Smoke?
 (3:00 - 3:50 PM, Convention Center/Room 203 Level 2-Meeting Room Level)
I. Grant

How Pot Can Cure Racism
(4:00 - 4:50 PM, Convention Center/Room 203 Level 2-Meeting Room Level)
C. Hart

50th Anniversary Social Hour
(5:00 – 5:50 PM, Hyatt Regency Denver Hotel Mineral Hall F)


Stacey

---
Stacey Sigmon, Ph.D.
Department of Psychiatry
College of Medicine

University of Vermont
UHC-SATC, Room 1415
1 S. Prospect Street
Burlington, VT 05401
P: (802) 656-9987
F: (802) 656-5793
E: stacey.sigmon@uvm.edu

[#DIV28SUPER] Help us celebrate Division 28's 50th Anniversary!

Please join us in celebrating Division 28's golden anniversary!  Our special symposium highlighting our Division's outstanding research history will be held at noon tomorrow in the Denver Convention Center.  Then join us for the 50th Anniversary Social Hour at 5pm tomorrow in the Hyatt's Mineral Hall F.  Look forward to seeing everyone tomorrow at these special events!



Fifty Years of Division 28 – Our Remarkable Past and Bright Future 
12:00 – 1:50 PM (CE), Convention Center Room 301

W. Bickel
In the Beginning a Response Was Reinforced: Conceptual Expansion in Addiction Science
 M. Carroll
Risk Factors for Drug Addiction and Novel Treatments: Preclinical Models
 R. Balster
The Role of Behavioral Pharmacology and Toxicology Research in Regulatory Science
M. Stitzer
Nicotine and Tobacco Research in Division 28
 S. Higgins
Division 28 and the Development of Contingency Management Interventions for Substance Use Disorders


50th Anniversary Social Hour
5:00 – 5:50 PM, Hyatt Regency Denver Hotel Mineral Hall F


Stacey

---
Stacey Sigmon, Ph.D.
Department of Psychiatry
College of Medicine

University of Vermont
UHC-SATC, Room 1415
1 S. Prospect Street
Burlington, VT 05401
P: (802) 656-9987
F: (802) 656-5793
E: stacey.sigmon@uvm.edu